课题基金 / 基金详情

Photodynamic Therapy Mediated by Cerenkov Light Emitted from Radiopharmaceut

Photodynamic Therapy Mediated by Cerenkov Light Emitted from Radiopharmaceut
放射性药物发出的切伦科夫光介导的光动力疗法
批准号:
8702867
负责人:
Simon R Cherry
金额:
$17.95万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2016-04-30

项目摘要

项目成果

Simon R Cherry的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A number of light-mediated therapies, such as photodynamic therapy (PDT), photoactivation and photochemical internalization have been, and are continuing to be, developed for treating cancer. Photodynamic therapy is used, or is under investigation, for a range of human tumors, but despite its well- documented strengths suffers a number of critical limitations: 1) The tumor has to be accessible to an external light source. 2) Achieving uniform and known dosimetry due to the uneven and rapid attenuation of light in tissue is a significant problem. 3) Photosensitizers are limited to those with reasonable absorption beyond 600 nm due to light penetration challenges. 4) Only detected tumors can be treated - ineffective against metastatic disease. Recently, the fact that many medical radionuclides emit optical photons via the Cerenkov effect has been exploited for imaging purposes. This emitted light is heavily weighted towards the ultraviolet and blue part of the spectrum. Furthermore, in nuclear medicine there are a wide range of tumor-targeted radiopharmaceuticals used both for diagnosis and at higher activity levels for therapy, that have good tumor specificity. This opens up the very interesting possibility of using the Cerenkov light generated from targeted radiopharmaceuticals as an "internal light source" to activate phototherapies such as PDT. If possible, this would circumvent many of the limitations of light delivery for PDT described above, as light would be emitted within the tumor cells, and the systemic injection of the radiopharmaceutical could potentially lead to PDT in both primary tumors and metastatic disease. There also may be synergistic effects of simultaneous PDT and radionuclide therapy. This exploratory R21 proposal will use in vitro and in vivo experiments to assess the feasibility of Cerenkov-activated PDT under well-controlled conditions and provide data that is necessary to determine if there is value in then pursuing this attractive concept in clinically-relevant preclinical trials in animals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier
  • 批准号:
    9240463
  • 项目类别:
  • 资助金额:
    $60.27万
  • 财政年份:
    2017
  • 负责人:
    Simon R Cherry
  • 依托单位:
Research at the interface of optical and ionizing radiation for innovative cancer imaging and therapy
Research at the interface of optical and ionizing radiation for innovative cancer imaging and therapy
Innovative Silicon Photomultiplier Technologies for Small-Animal PET
海外基金